Drugs Containing Excipient (Inactive Ingredient) RED 40 LAKE

« Back to Dashboard

Generic drugs containing RED 40 LAKE excipient

Company	Ingredient	NDC	Excipient
A-S Medication Solutions	hydrochlorothiazide	50090-7764	RED 40 LAKE
A-S Medication Solutions	hydrochlorothiazide	50090-7765	RED 40 LAKE
A-S Medication Solutions	diclofenac sodium	50090-7855	RED 40 LAKE
A-S Medication Solutions	diclofenac sodium	50090-7856	RED 40 LAKE

Red 40 Lake Pharmaceutical Market Dynamics and Financial Trajectory

Last updated: November 6, 2026

Red 40 Lake is a regulated synthetic color additive used in pharmaceutical tablets, capsules, chewables, syrups, supplements, and topical products. Its market is fragmented, price-sensitive, and controlled by regulatory compliance rather than patent exclusivity. Public companies do not report Red 40 Lake revenue separately, so the product’s financial trajectory must be assessed through color-additive demand, pharmaceutical manufacturing volumes, raw-material costs, regulatory exposure, and supplier disclosures.

What is Red 40 Lake and how is it used in pharmaceuticals?

Red 40 Lake is the aluminum-lake form of FD&C Red No. 40, also known as Allura Red AC and Color Index 16035. Unlike water-soluble Red 40 dye, the lake is an insoluble pigment dispersed in a solid or semisolid formulation.

Its pharmaceutical functions include:

• Tablet and capsule coloration
• Product identification and differentiation
• Protection against formulation variability
• Color matching for branded dosage forms
• Appearance enhancement in chewables, lozenges, and oral liquids
• Coloring of topical products and certain medical foods

The lake form is particularly useful in tablets and hard-shell capsules because it is less water-soluble than the dye form. This can improve color retention in dry processing and reduce migration between adjacent dosage-form components.

Red 40 Lake is an inactive ingredient rather than an active pharmaceutical ingredient. FDA’s Inactive Ingredient Database provides a regulatory reference for inactive ingredients used in approved drug products, while color additives remain subject to separate color-additive regulations and batch-certification requirements where applicable [1][2].

What is the regulatory status of Red 40 Lake?

In the United States, FD&C Red No. 40 and its aluminum lake are regulated under the Federal Food, Drug, and Cosmetic Act and Title 21 of the Code of Federal Regulations. The applicable lake provision is generally associated with 21 C.F.R. Part 82, including the listing for FD&C Red No. 40 aluminum lake [2].

FDA status

Key U.S. regulatory characteristics include:

Regulatory issue	Red 40 Lake status
FDA category	Certified color additive
U.S. use	Permitted in specified foods, drugs, and cosmetics subject to applicable limits
Drug role	Inactive ingredient
Batch certification	Required for certified color additives
Orange Book listing	No
New drug exclusivity	No
Patent exclusivity	No product-specific exclusivity
ANDA relevance	Ingredient and formulation compliance remain relevant
Safety review	Subject to FDA color-additive regulation and toxicological review

Manufacturers generally need certified material supported by a certificate of analysis, identity testing, purity controls, heavy-metal controls, microbial controls where relevant, and documentation of the aluminum substrate and manufacturing process.

European and international status

The equivalent food color designation is commonly E129, although authorization, concentration limits, labeling rules, and pharmaceutical use differ by jurisdiction. European pharmaceutical manufacturers must also consider the European Medicines Agency’s expectations for excipient quality, control strategy, and risk assessment [3].

The commercial consequence is geographic segmentation. A supplier selling into the United States, European Union, India, China, Japan, and regulated emerging markets may need separate documentation packages, specifications, labeling formats, and regulatory assessments.

How large is the Red 40 Lake pharmaceutical market?

No authoritative public source reports a standalone global market size for Red 40 Lake used in pharmaceuticals. Market-research reports commonly combine synthetic food colors, pharmaceutical colorants, nutraceutical colorants, and cosmetic pigments, making product-level revenue estimates unreliable.

A useful market model is:

Red 40 Lake pharmaceutical revenue = dosage-form volume × colorant loading × average selling price × regulated-market mix

The market is small compared with pharmaceutical active ingredients and large excipients such as microcrystalline cellulose, lactose, starch, and magnesium stearate. It is also more specialized than the broader synthetic food-color market.

Principal demand segments

Segment	Demand role	Commercial characteristics
Solid oral pharmaceuticals	Core use	Stable demand, low loading per unit, qualification-sensitive
OTC products	Significant use	Strong branding and color differentiation
Nutraceuticals	Important adjacent market	Higher design flexibility, more private-label exposure
Confectionery and food	Large volume competitor	Can absorb supplier capacity and affect pricing
Cosmetics	Secondary market	Different purity, shade, and regional requirements
Veterinary products	Smaller opportunity	Product identification and palatability support

Pharmaceutical demand is relatively resilient because the quantity of color per tablet is low and colorant cost is usually a minor share of finished-product cost. A product manufacturer may continue purchasing a qualified color even when the price rises because changing the shade can trigger stability work, visual-equivalence testing, regulatory filings, and manufacturing requalification.

What factors are driving Red 40 Lake market dynamics?

Demand from oral dosage forms

The largest pharmaceutical opportunity is in branded and generic oral dosage forms where color is used to distinguish strengths, improve patient recognition, or preserve brand appearance. Growth in generic medicines, OTC products, chewable tablets, and dietary supplements supports baseline demand.

Colorant demand does not scale directly with drug revenue. A high-value medicine may use only a small quantity of Red 40 Lake, while a high-volume low-cost tablet can create more physical demand.

Supplier qualification and switching costs

Once a pharmaceutical manufacturer qualifies a supplier and shade, switching is operationally difficult. The buyer may need to repeat:

• Incoming-material qualification
• Shade and particle-size comparisons
• Blend-uniformity studies
• Stability studies
• Cleaning validation assessments
• Regulatory documentation updates
• Artwork or appearance reviews

These switching costs give qualified suppliers more pricing protection than a basic commodity model would suggest. The protection is limited, however, because multiple global and regional color manufacturers offer synthetic red lakes.

Raw-material and energy costs

Red 40 Lake economics depend on synthetic dye intermediates, aluminum substrates, acids, alkalis, water, energy, labor, waste treatment, packaging, and regulatory testing. Manufacturing is exposed to:

• Petrochemical and aromatic-intermediate costs
• Aluminum compound pricing
• Electricity and natural-gas costs
• Freight and container rates
• Environmental compliance costs
• Currency movements in India, China, Europe, and the United States

Supplier margins can contract quickly when input costs rise but customer contracts limit immediate price pass-through.

Regulatory pressure

Regulatory scrutiny is a larger commercial risk than patent litigation. Buyers may seek alternatives because of:

• Consumer concern over synthetic colors
• State-level or national restrictions
• Labeling requirements
• Reformulation toward natural colors
• Limits on contaminants or residual intermediates
• Customer policies excluding certain artificial colors

The United States and European Union remain important reference markets, but regulatory treatment can diverge. A restriction in one market does not automatically eliminate pharmaceutical demand worldwide.

What companies supply Red 40 Lake?

The supply base includes multinational color and ingredient companies, specialized synthetic-color manufacturers, and regional producers. Publicly visible participants in the wider colorant and pharmaceutical-color ecosystem include Sensient Technologies, D.D. Williamson and Company, ROHA Group, Vidhi Specialty Food Ingredients, Dynemic Products, and other manufacturers in India, China, Europe, and the United States.

The supplier landscape is not equivalent to a branded-drug market. Companies often report colorants within broader segments such as:

• Food colors
• Pharmaceutical colors
• Cosmetic colors
• Natural and synthetic ingredients
• Specialty chemicals
• Functional excipients

Sensient, for example, reports color and flavor operations at a segment level rather than identifying Red 40 Lake sales separately [4]. Similar aggregation applies to most private and public suppliers.

Competitive factors

Competitive factor	Impact on market
FDA certification capability	Raises barriers for U.S. pharmaceutical supply
Shade consistency	Supports customer retention
Particle-size control	Affects dispersion and dosage-form performance
Global documentation	Enables multinational contracts
Multi-site supply	Reduces shortage risk
Natural-color portfolio	Helps defend against reformulation
Cost position	Important in generic and supplement markets
Regulatory history	Influences qualification decisions

What is the financial trajectory for Red 40 Lake?

The likely financial trajectory is stable to moderately growing in nominal terms, with margin volatility. The product does not have the pricing power of a patented pharmaceutical ingredient. Revenue growth depends primarily on volume, mix, and price adjustments.

Base-case trajectory

The base case has four characteristics:

1. Pharmaceutical volumes grow with global oral-dose manufacturing.
2. Unit prices rise intermittently with compliance, energy, and logistics costs.
3. Synthetic-color substitution limits long-term volume growth.
4. Qualified pharmaceutical suppliers retain customers longer than food-market suppliers.

A reasonable commercial expectation is low-single-digit underlying volume growth in established pharmaceutical markets, with higher growth possible in emerging-market generics, OTC products, and nutraceuticals. This is a market framework rather than a reported Red 40 Lake forecast because no public company discloses the product as a standalone reporting unit.

Margin outlook

Margins should be strongest for:

• Certified pharmaceutical-grade material
• Custom shades
• Low-contaminant or low-metal specifications
• Small-batch and development quantities
• Dual-compendial or multinational documentation
• Products supported by technical and regulatory services

Margins should be weaker for:

• Large-volume standard shades
• Food-grade competition
• Spot-market purchases
• Customers with multiple qualified suppliers
• Regions with aggressive price competition

A supplier with manufacturing in India or China may have a cost advantage, but this advantage can be offset by freight, qualification requirements, import controls, and customer demand for regional redundancy.

Does Red 40 Lake have patents, exclusivity, or Orange Book protection?

Red 40 Lake has no pharmaceutical patent moat comparable to an active drug molecule, formulation patent, or drug-device combination.

IP or regulatory right	Relevance to Red 40 Lake
Composition-of-matter patent	Generally not a current commercial barrier
Orange Book patent	None
FDA NCE exclusivity	None
Orphan-drug exclusivity	None
Pediatric exclusivity	None
Paragraph IV litigation	Not applicable to the colorant itself
Biosimilar litigation	Not applicable
Supplier know-how	Potentially relevant
Process controls	Commercially relevant but usually not publicly visible
Custom shade specification	Customer-retention advantage rather than statutory exclusivity

Manufacturing know-how can protect yield, shade consistency, particle-size distribution, impurity control, and scale-up performance. Those advantages are difficult to value from public records and are not equivalent to enforceable market exclusivity.

What formulation and manufacturing risks affect pharmaceutical buyers?

The main formulation risks relate to performance and compliance rather than patent infringement.

Formulation considerations

Red 40 Lake selection can affect:

• Color uniformity
• Blend segregation
• Tablet appearance
• Film-coating behavior
• Dissolution if excessive coating or hydrophobicity is introduced
• Light stability
• Interaction with excipients
• Capsule-shell appearance
• Cleaning requirements
• Batch-to-batch visual consistency

Pharmaceutical companies typically qualify the colorant against a defined particle-size range, shade standard, assay or strength, loss on drying, residue, impurities, and microbiological specification where applicable.

Manufacturing barriers

A credible supplier must manage:

• Certified color-additive production
• Aluminum-lake formation
• Filtration and drying
• Milling and particle-size control
• Trace-metal and impurity testing
• Lot traceability
• Change-control notification
• Regulatory documentation
• Supply continuity

These requirements create operational barriers but do not prevent market entry by a technically capable competitor.

Which companies are challenging Red 40 Lake demand?

The principal competitive threat is substitution rather than litigation. Alternatives include:

• Red 40 dye
• Carmine and cochineal
• Beet-derived colors
• Anthocyanins
• Paprika oleoresin blends
• Synthetic reds such as Ponceau-related systems where permitted
• Iron oxides for certain red or brown shades
• Custom natural-color systems

Natural substitutes often have weaker stability, higher cost, narrower pH tolerance, or different shade characteristics. Synthetic Red 40 Lake therefore retains a performance and cost position in many solid-dose applications. Reformulation pressure is strongest in consumer-facing products, pediatric products, supplements, and brands with “clean label” positioning.

What is the generic launch risk for products using Red 40 Lake?

The colorant itself does not create a Paragraph IV barrier. An ANDA applicant can use Red 40 Lake if the proposed product meets applicable FDA requirements and matches the reference product’s inactive-ingredient and product-quality expectations.

Generic launch risk is therefore indirect:

• A supplier change can cause color mismatch
• A different particle-size distribution can affect processing
• A substitute color can alter appearance or stability
• Documentation gaps can delay regulatory review
• A shortage can interrupt commercial production
• A branded product may rely on appearance for market differentiation

For most products, Red 40 Lake is a manageable supply-chain issue rather than a launch-blocking exclusivity right.

What are the key financial risks and opportunities?

Risks

• Synthetic-color restrictions
• Reclassification or tighter contaminant limits
• Raw-material inflation
• Customer concentration
• Supplier qualification failures
• Regional trade restrictions
• Environmental compliance costs
• Substitution by natural colors
• Price erosion in generic pharmaceuticals
• Lack of product-level reporting transparency

Opportunities

• Dual-certified pharmaceutical and food supply
• Natural-color replacement systems
• Custom shade development
• Direct supply agreements with contract manufacturers
• Regional production redundancy
• Pharmaceutical-grade documentation services
• Expansion in generic and OTC manufacturing
• Higher-value low-metal and low-impurity grades

Key Takeaways

• Red 40 Lake is a regulated pharmaceutical color additive, not an active drug ingredient.
• Its core pharmaceutical applications are tablets, capsules, chewables, oral liquids, and some topical products.
• No Orange Book listing, Paragraph IV pathway, drug exclusivity, or biosimilar risk applies to Red 40 Lake itself.
• The market is fragmented and no reliable public source reports standalone global pharmaceutical revenue.
• Financial performance is driven by dosage-form volumes, supplier qualification, raw-material costs, regional regulation, and reformulation trends.
• Qualified suppliers can maintain customer relationships through shade consistency, documentation, and change-control performance.
• The principal competitive threat is substitution by natural colors or alternative synthetic pigments, not patent litigation.
• The base commercial outlook is stable to moderately growing, with low-single-digit volume growth and periodic margin pressure.

FAQs

Is Red 40 Lake the same as FD&C Red No. 40?

No. FD&C Red No. 40 is the underlying certified color family. Red 40 Lake is the insoluble aluminum-lake form, while Red 40 dye is water-soluble.

Is Red 40 Lake an active pharmaceutical ingredient?

No. It is an inactive ingredient used primarily for coloration, identification, and product appearance.

Can a generic manufacturer use Red 40 Lake?

Yes, subject to FDA requirements for inactive ingredients, color-additive compliance, product quality, and applicable ANDA documentation.

Does Red 40 Lake affect pharmaceutical dissolution?

It can affect processing and, in some formulations, coating or wetting behavior. The impact depends on concentration, particle size, dosage form, and the other excipients.

Is Red 40 Lake expected to lose market share to natural colors?

It may lose share in consumer-facing products where natural-color positioning is important. Its cost, stability, and shade consistency continue to support use in many pharmaceutical and OTC formulations.

References

1. U.S. Food and Drug Administration. (n.d.). Inactive ingredient database. https://www.accessdata.fda.gov/scripts/cder/iig/index.cfm

2. U.S. Food and Drug Administration. (n.d.). Electronic Code of Federal Regulations, Title 21, Parts 74 and 82: Color additives. https://www.ecfr.gov/current/title-21/chapter-I/subchapter-A/part-82

3. European Medicines Agency. (2011). Guideline on excipients in the dossier for application for marketing authorisation of a medicinal product. https://www.ema.europa.eu/

4. Sensient Technologies Corporation. (2024). Annual report. https://www.sensient.com/investors/financial-information/annual-reports